Prometic Life Sciences Inc. J (T:PLI*CA)
Business Focus: N/A
Oct 03, 2019 10:56 am ET
Prometic Shareholders Approve Name Change to Liminal BioSciences Inc.
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Oct. 3, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced results from the special meeting of shareholders held in Montreal, Quebec, on October 3, 2019. Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences
Sep 09, 2019 08:00 am ET
Prometic Reports First Subject Dosed in Phase I Clinical Study with Single Ascending Doses of PBI-4547
Novel, orally active immuno-metabolic agent Potential therapy for NAFLD/NASH, metabolic syndrome and other liver diseases Fully owned and proprietary to Prometic LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Sept. 9, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in liver, respiratory, and kidney diseases, announced today that the first subject has been dosed in a Phase I clinical study of PBI-4547. PBI-4547 is a novel, orally active immune-metabolic age
Sep 04, 2019 08:00 am ET
Prometic Life Sciences to Present at H.C. Wainwright & Co. 21st Annual Global Investment Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Sept. 4, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the H.C. Wainwright & Co. 21st Annual Global Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York, USA.
Sep 03, 2019 06:53 pm ET
Prometic Life Sciences Announces Intention to Change Name to Liminal BioSciences Inc.
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Aug 12, 2019 06:45 pm ET
Prometic reports financial results for second quarter 2019
C$229 (US 173) million of outstanding debt converted into Common Shares C$114 (US$87) million in gross proceeds raised in concurrent financings Internal promotions within the management team for Chief Financial Officer and General Counsel LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Aug. 12, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or "Company"), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, primarily in rare or orphan diseases, today an
Aug 08, 2019 08:00 am ET
Correction of previous press release: Prometic to report its second quarter financial results and hold conference call
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Aug. 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), wishes to correct an error in its press release entitled "Prometic to report its second quarter financial results and hold a conference call" issued on August 7th, 2019. Prometic's conference call will be held at 8:30 a.m. (EDT), rather than 11:00 a.m. (EDT) on Tuesday, August 13th, 2019.
Aug 07, 2019 08:00 am ET
Prometic to report its second quarter financial results and hold conference call
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Aug. 7, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it will report its financial results for the second quarter ended June 30th, 2019 on Monday August 12th, 2019 after market close.
Aug 05, 2019 05:40 pm ET
Prometic Life Sciences to Present at Canaccord 39th Annual Growth Conference
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Aug. 5, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the Canaccord 39th Annual Growth Conference at 16:30 ET on Wednesday, August 7, 2019 in Boston, USA.
Jul 02, 2019 08:30 am ET
Prometic Announces Share Consolidation
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jun 19, 2019 06:58 pm ET
Prometic Announces Voting Results of its 2019 AGM
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, June 19, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced the voting results from its 2019 Annual General and Special Meeting of Shareholders ("AGM") held in Montreal, Quebec. A total of 16,792,591,957 common shares were voted, representing 81.04% of the votes attached to the issued and outstanding common shares of Prometic.
Jun 17, 2019 08:30 am ET
Prometic announces completion of equity rights offering
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jun 14, 2019 03:30 am ET
Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, June 14, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that four abstracts highlighting Prometic's progress in developing PBI-4050 as a potential treatment for both acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the 56th Congress of the European Renal Association - European Dialysis and Transplant Associat
May 30, 2019 09:00 am ET
Prometic Life Sciences to Present at Two Upcoming June Investor Conferences
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, May 30, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the 2019 Jeffries Global Healthcare Conference at 14:30 EDT on Thursday, June 6, 2019 and at the Raymond James Life Sciences & MedTech Conference at 15:35 EDT on Wednesday, June 19, both in New York,
May 22, 2019 08:30 am ET
Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference
LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™ (plasminogen), on lung fibrosis indications, at the American Thoracic Society (ATS) 2019 International Conference taking place in Dallas, Texas, from May 17 – 22, 2019.
May 22, 2019 08:30 am ET
Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference
LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™ (plasminogen), on lung fibrosis indications, at the American Thoracic Society (ATS) 2019 International Conference taking place in Dallas, Texas, from May 17 – 22, 2019.
May 15, 2019 03:08 pm ET
Prometic announces terms of equity rights offering
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
May 08, 2019 07:46 pm ET
Prometic reports its 2019 first quarter financial results
Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering New CEO, Board appointees and management structure to strengthen Corporation's leadership $8.2 million in revenues for Q1-2019 compared to $4.3 million for Q1-2018 Net loss of $28.8 million for Q1-2019 compared to Net loss $34.6 million for Q1-2018 LAVAL, QC, May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") reported today its unaudited financial results for the first quarter ended March 31, 2019.
May 08, 2019 07:46 pm ET
Prometic reports its 2019 first quarter financial results
Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering New CEO, Board appointees and management structure to strengthen Corporation's leadership $8.2 million in revenues for Q1-2019 compared to $4.3 million for Q1-2018 Net loss of $28.8 million for Q1-2019 compared to Net loss $34.6 million for Q1-2018 LAVAL, QC, May 8, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") reported today its unaudited financial results for the first quarter ended March 31, 2019.
May 08, 2019 06:31 pm ET
Prometic strengthens its leadership with a new management structure and the appointment of three new directors
LAVAL, QC and CAMBRIDGE, United Kingdom, May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or "Corporation") is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors. All three of these individuals will be included as nominees for election to the Board of Directors by shareholders at the upcoming Annual General and Special Meeting of the shareholders ("AGM") scheduled to take place in Montreal, Québec, Can
May 08, 2019 06:31 pm ET
Prometic strengthens its leadership with a new management structure and the appointment of three new directors
LAVAL, QC and CAMBRIDGE, United Kingdom, May 8, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or "Corporation") is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors. All three of these individuals will be included as nominees for election to the Board of Directors by shareholders at the upcoming Annual General and Special Meeting of the shareholders ("AGM") scheduled to take place in Montreal, Québec, Can
Apr 23, 2019 12:33 pm ET
Prometic Completes Refinancing Transactions Including C$75 Million (approximately US$56 Million) in Gross Proceeds from New Equity Financing
Stefan Clulow appointed as Chair of the Board Kenneth Galbraith appointed as Chief Executive Officer/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Apr 15, 2019 07:00 am ET
Prometic Announces Refinancing Transactions
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Apr 01, 2019 06:20 pm ET
Prometic reports fourth quarter and 2018 year-end financial results
Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net loss of $ 237.9 million for the year ended December 31, 2018 includes a non-cash writedown of intangible assets related to IVIG of $ 150.0 million Near-term financing shortfall requires urgent action to restructure the Corporation's indebtedness and raise capital LAVAL, QC, April 1, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic or the Corporation) reported today its financial result
Apr 01, 2019 06:20 pm ET
Prometic reports fourth quarter and 2018 year-end financial results
Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net loss of $ 237.9 million for the year ended December 31, 2018 includes a non-cash writedown of intangible assets related to IVIG of $ 150.0 million Near-term financing shortfall requires urgent action to restructure the Corporation's indebtedness and raise capital LAVAL, QC, April 1, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic or the Corporation) reported today its financial result
Mar 26, 2019 12:32 pm ET
Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast
LAVAL, QC, March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close.
Mar 26, 2019 12:32 pm ET
Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast
LAVAL, QC, March 26, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close.
Mar 25, 2019 07:00 am ET
Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
LAVAL, QC, March 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $5 million (CAD $6.7 million) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017. The proceeds of this loan extension will be used to satisfy the near-term cash requirements of the Corporation.
Mar 25, 2019 07:00 am ET
Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
LAVAL, QC, March 25, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $5 million (CAD $6.7 million) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017. The proceeds of this loan extension will be used to satisfy the near-term cash requirements of the Corporation.
Feb 25, 2019 06:00 am ET
Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
LAVAL, QC, Feb. 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017. Other than the extension of this additional tranche, the provisions of the existing credit facilities with SALP remain in full force and effect.
Feb 25, 2019 06:00 am ET
Prometic secures additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities
LAVAL, QC, Feb. 25, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017. Other than the extension of this additional tranche, the provisions of the existing credit facilities with SALP remain in full force and effect.
Feb 14, 2019 06:00 am ET
Prometic retains investment bank for strategic transactions
LAVAL, QC, Feb. 14, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI), (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation focused on maximizing shareholder value. These transactions could include, among other things, the out-licensing of drug candidates and monetization of non-core assets.
Feb 14, 2019 06:00 am ET
Prometic retains investment bank for strategic transactions
LAVAL, QC, Feb. 14, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI), (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation focused on maximizing shareholder value. These transactions could include, among other things, the out-licensing of drug candidates and monetization of non-core assets.
Dec 19, 2018 06:30 am ET
Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences
LAVAL, QC, Dec. 19, 2018 /CNW/ - The Board of Directors of Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately. Prof. Best has been the Chairman of the Prometic Board of Directors since May 2014 and has over 30 years of global life sciences expertise with a focus on business development, strategic planning and product commercialization. He has served as CEO of several biotech companies and as both Vice-Chair of the US Biotechnology Industry Organis
Dec 19, 2018 06:30 am ET
Prof. Simon Best Appointed Interim CEO of Prometic Life Sciences
LAVAL, QC, Dec. 19, 2018 /PRNewswire/ - The Board of Directors of Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately. Prof. Best has been the Chairman of the Prometic Board of Directors since May 2014 and has over 30 years of global life sciences expertise with a focus on business development, strategic planning and product commercialization. He has served as CEO of several biotech companies and as both Vice-Chair of the US Biotechnology Industry
Dec 05, 2018 08:34 am ET
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
Clinical-regulatory pathway defined following recent meetings with regulatory authorities Pivotal Phase 3 clinical trial design finalized to support regulatory submissions in the U.S. and Europe Provides potential for faster route to regulatory approval with Alström syndrome Opens an efficient route to market for PBI-4050 and potential to monetize Prometic's second PRV LAVAL, QC, Dec. 5, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today confirmed its decision to formally pursue Alström syndrome (AS) as a clinical indication for
Dec 05, 2018 08:34 am ET
Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome
Clinical-regulatory pathway defined following recent meetings with regulatory authorities Pivotal Phase 3 clinical trial design finalized to support regulatory submissions in the U.S. and Europe Provides potential for faster route to regulatory approval with Alström syndrome Opens an efficient route to market for PBI-4050 and potential to monetize Prometic's second PRV LAVAL, QC, Dec. 5, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today confirmed its decision to formally pursue Alström syndrome (AS) as a clinical indication for
Nov 28, 2018 06:00 am ET
Prometic Provides Corporate Update
LAVAL, QC, Nov 28, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") has previously announced a series of initiatives to lengthen its cash runway to better position the Corporation to achieve its objectives. These include a significant reduction in the Corporation's cash use in 2019, driven in part by significant growth in its bioseparation revenues, a reduction of anticipated R&D expenditures by up to $30 million as compared to projected 2018 levels, as well as the extension of the maturity dates of all of the Corporation's outs
Nov 28, 2018 06:00 am ET
Prometic Provides Corporate Update
LAVAL, QC, Nov 28, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") has previously announced a series of initiatives to lengthen its cash runway to better position the Corporation to achieve its objectives. These include a significant reduction in the Corporation's cash use in 2019, driven in part by significant growth in its bioseparation revenues, a reduction of anticipated R&D expenditures by up to $30 million as compared to projected 2018 levels, as well as the extension of the maturity dates of all of the Corporation's outs
Nov 14, 2018 07:39 pm ET
Prometic Reports Third Quarter 2018 Financial Results and Highlights
Extension of maturity dates of Line of Credit and OID Loans to September 2024 Implementation of cost control measures to significantly reduce operational burn and extend cash runway Substantial reduction in R&D costs of up to $30 million in 2019 versus 2018 Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process Q3 revenues of $12.3 million Granted Rare Pediatric Disease Designation by FDA for PBI-4050 to treat Alström Syndrome LAVAL, QC, Nov. 14, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)
Nov 14, 2018 07:39 pm ET
Prometic Reports Third Quarter 2018 Financial Results and Highlights
Extension of maturity dates of Line of Credit and OID Loans to September 2024 Implementation of cost control measures to significantly reduce operational burn and extend cash runway Substantial reduction in R&D costs of up to $30 million in 2019 versus 2018 Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process Q3 revenues of $12.3 million Granted Rare Pediatric Disease Designation by FDA for PBI-4050 to treat Alström Syndrome LAVAL, QC, Nov. 14, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)
Nov 14, 2018 11:51 am ET
Prometic Closes its Extension of Debt Maturities to 2024
Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 One of a number of measures underway to extend cash runway Significant reduction in R&D costs of up to $30 million in 2019 LAVAL, QC, Nov. 14, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the transaction previously disclosed on October 29, 2018 with Structured Alpha LP (SALP), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., extending the maturity dates of its USD $80
Nov 14, 2018 11:51 am ET
Prometic Closes its Extension of Debt Maturities to 2024
Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024 One of a number of measures underway to extend cash runway Significant reduction in R&D costs of up to $30 million in 2019 LAVAL, QC, Nov. 14, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the transaction previously disclosed on October 29, 2018 with Structured Alpha LP (SALP), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., extending the maturity dates of its USD $80
Nov 12, 2018 04:34 pm ET
Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast
LAVAL, QC, Nov. 12, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.
Nov 12, 2018 04:34 pm ET
Prometic to Report its Third Quarter 2018 Financial Results and Hold Conference Call / Webcast
LAVAL, QC, Nov. 12, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.
Oct 29, 2018 07:00 am ET
Prometic Announces Extension of Debt Maturities to 2024
Maturity Date of Line of Credit to be Extended from November 2019 to September 2024 Maturity Date of Long-Term (OID) Loans to be Extended from July 2022 to September 2024 LAVAL, QC, Oct. 29, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has signed a binding letter of intent with Structured Alpha LP (SALP), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., to extend the maturity dates of its USD $80 million (CAD $100 million) line of credit and Original Issue Discount Notes
Oct 29, 2018 07:00 am ET
Prometic Announces Extension of Debt Maturities to 2024
Maturity Date of Line of Credit to be Extended from November 2019 to September 2024 Maturity Date of Long-Term (OID) Loans to be Extended from July 2022 to September 2024 LAVAL, QC, Oct. 29, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has signed a binding letter of intent with Structured Alpha LP (SALP), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., to extend the maturity dates of its USD $80 million (CAD $100 million) line of credit and Original Issue Discount Notes
Oct 25, 2018 03:37 pm ET
Prometic announces second annual Plasminogen Deficiency Awareness Week
LAVAL, QC, Oct. 25, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to invite you to its second annual Plasminogen Deficiency Awareness Week, from November 5 to 8, 2018.
Oct 16, 2018 06:30 am ET
Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA
Implementation plan for additional analytical assays and in-process controls confirmed Company finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing of RYPLAZIM™ (plasminogen) conformance lots LAVAL, QC, Oct. 16, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has completed a Type C meeting in which the FDA agreed with the Company's proposed action plan for the implementation of additional analytical assays and in-process controls related to Ryplazim™ (plasmi
Oct 16, 2018 06:30 am ET
Prometic announces positive feedback from FDA Type-C meeting on Ryplazim™ (plasminogen) BLA
Implementation plan for additional analytical assays and in-process controls confirmed Company finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing of RYPLAZIM™ (plasminogen) conformance lots LAVAL, QC, Oct. 16, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has completed a Type C meeting in which the FDA agreed with the Company's proposed action plan for the implementation of additional analytical assays and in-process controls related to Ryplazim™ (plasmi
Sep 05, 2018 12:23 pm ET
Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)
LAVAL, QC, Sept. 5, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported today that it will host a Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome (AS) and a promising therapeutics candidate for the treatment of non-alcoholic steatohepatitis (NASH) on Friday, September 7th in New York City.
Sep 05, 2018 12:23 pm ET
Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)
LAVAL, QC, Sept. 5, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported today that it will host a Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome (AS) and a promising therapeutics candidate for the treatment of non-alcoholic steatohepatitis (NASH) on Friday, September 7th in New York City.
Aug 14, 2018 06:07 pm ET
Prometic Reports Second Quarter 2018 Financial Results and Highlights
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)
Submitted plan to FDA regarding filing of the amended BLA for RyplazimTM (plasminogen)
Q2 revenues of $20.2 million, and net loss of $33.1 million. R&D and Admin costs down from the same period in 2017.
Received Rare Pediatric Disease Designation for PBI-4050 from the FDA for the treatment of Alström Syndrome
Presented new clinical data for PBI-4050 and PBI-4547 in liver fibrosis and for IVIG in PIDD demonstrating signs of posit
Aug 14, 2018 06:07 pm ET
Prometic Reports Second Quarter 2018 Financial Results and Highlights
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen)
Submitted plan to FDA regarding filing of the amended BLA for RyplazimTM (plasminogen)
Q2 revenues of $20.2 million, and net loss of $33.1 million. R&D and Admin costs down from the same period in 2017.
Received Rare Pediatric Disease Designation for PBI-4050 from the FDA for the treatment of Alström Syndrome
Presented new clinical data for PBI-4050 and PBI-4547 in liver fibrosis and for IVIG in PIDD demonstrating signs of posit
Aug 10, 2018 07:15 am ET
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
PBI-4050 reduces the activation of hepatic stellate cells, the major cells involved in liver fibrosis
PBI-4050 decreases liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway
AMPK acts as the "master regulator" of cellular energy homeostasis and its role in reducing fibrosis is well documented
LAVAL, QC, Aug. 10, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced the publication of a paper further elucidating the mechanism of action of its lead drug candidate, PBI-4050, on liver fibrosis in the Journal of Pharmacology and Exper
Aug 10, 2018 07:15 am ET
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
PBI-4050 reduces the activation of hepatic stellate cells, the major cells involved in liver fibrosis
PBI-4050 decreases liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway
AMPK acts as the "master regulator" of cellular energy homeostasis and its role in reducing fibrosis is well documented
LAVAL, QC, Aug. 10, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced the publication of a paper further elucidating the mechanism of action of its lead drug candidate, PBI-4050, on liver fibrosis in the Journal of Pharmacology and Exper
Aug 07, 2018 02:21 pm ET
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.
Aug 07, 2018 02:21 pm ET
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
LAVAL, QC, Aug. 7, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.
Aug 07, 2018 07:00 am ET
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050
Rare Pediatric Disease Designation granted for the treatment of patients with Alström syndrome
Third Rare Pediatric Disease Designation obtained by Prometic
LAVAL, QC, Aug. 7, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to its small molecule drug candidate, PBI-4050, for the treatment of Alström syndrome (AS). In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA an
Aug 07, 2018 07:00 am ET
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050
Rare Pediatric Disease Designation granted for the treatment of patients with Alström syndrome
Third Rare Pediatric Disease Designation obtained by Prometic
LAVAL, QC, Aug. 7, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to its small molecule drug candidate, PBI-4050, for the treatment of Alström syndrome (AS). In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA an
Jun 22, 2018 12:38 pm ET
Prometic conference call to present progress report on AGM corporate action plan
LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th.
Jun 22, 2018 12:38 pm ET
Prometic conference call to present progress report on AGM corporate action plan
LAVAL, QC, June 22, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th.
Jun 22, 2018 07:00 am ET
Prometic Presents New Data on NASH Drug Candidate PBI-4547
New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity
New data to be presented at the 2018 American Diabetes Association conference
LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of four posters at the American Diabetes Association's 78th Scientific Sessions taking place in Orlando, Florida, June 22 – 26, 2018. The posters and data to be presented at the conference sugges
Jun 22, 2018 07:00 am ET
Prometic Presents New Data on NASH Drug Candidate PBI-4547
New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity
New data to be presented at the 2018 American Diabetes Association conference
LAVAL, QC, June 22, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of four posters at the American Diabetes Association's 78th Scientific Sessions taking place in Orlando, Florida, June 22 – 26, 2018. The posters and data to be presented at the conference sugges
Jun 08, 2018 05:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
Results of the Quarterly Review of the S&P/TSX Composite Index
May 22, 2018 01:31 pm ET
Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
Treatment with PBI-4050 for 12 weeks positively affected biomarkers known to have antifibrotic activity
New clinical data presented at the American Thoracic Society 2018 International Conference
LAVAL, QC, May 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced an oral presentation of new clinical data assessing the effect of its lead small molecule candidate, PBI-4050, on blood biomarkers for the treatment of idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2018 International Conference. Four additional poster
May 15, 2018 05:44 pm ET
Prometic reports its 2018 first quarter highlights and financial results
Q1 results support expected 2018 full year spending decrease of approximately $15M
Sale of excess plasma inventory completed in April contributing $14M to proforma cash runway of $91M
Clinical programs streamlined to manage costs for balance of 2018
Continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions
LAVAL, QC, May 15, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) reported today its unaudited financial results for the first quarter ended March 31, 2018.
May 15, 2018 05:44 pm ET
Prometic reports its 2018 first quarter highlights and financial results
Q1 results support expected 2018 full year spending decrease of approximately $15M
Sale of excess plasma inventory completed in April contributing $14M to proforma cash runway of $91M
Clinical programs streamlined to manage costs for balance of 2018
Continued positive clinical activity demonstrated by PBI-4050 to catalyze partnership discussions
LAVAL, QC, May 15, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) reported today its unaudited financial results for the first quarter ended March 31, 2018.
May 10, 2018 05:13 pm ET
Prometic reports on its 2018 annual and special meeting of shareholders highlights
LAVAL, QC, May 10, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today reported the highlights from its 2018 annual and special meeting of shareholders and Board of Directors election results.
May 10, 2018 05:13 pm ET
Prometic reports on its 2018 annual and special meeting of shareholders highlights
LAVAL, QC, May 10, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today reported the highlights from its 2018 annual and special meeting of shareholders and Board of Directors election results.
Apr 30, 2018 06:30 am ET
Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Clinical data presented at the Clinical Immunology Society Annual Meeting in Toronto, Canada on April 27-28, 2018
Pivotal clinical trial meets primary and secondary endpoints
Clinical data demonstrates comparable efficacy to commercially-approved drugs
Prometic IVIG's safety and tolerability profiles maintained without any significant drug related issues
LAVAL, QC, April 30, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced positive clinical data from its pivotal IVIG phase 3 clinical trial, meeting its clinical primary and secondary end
Apr 30, 2018 06:30 am ET
Prometic Reports Positive Clinical Data from its Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Clinical data presented at the Clinical Immunology Society Annual Meeting in Toronto, Canada on April 27-28, 2018
Pivotal clinical trial meets primary and secondary endpoints
Clinical data demonstrates comparable efficacy to commercially-approved drugs
Prometic IVIG's safety and tolerability profiles maintained without any significant drug related issues
LAVAL, QC, April 30, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced positive clinical data from its pivotal IVIG phase 3 clinical trial, meeting its clinical primary and secondary end
Apr 12, 2018 06:30 am ET
Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial
New clinical data presented at the International Liver CongressTM 2018
PBI-4050 decreased insulin resistance in the liver
Fat biopsies further demonstrate PBI-4050 clinical activity
Clinical activity measured in the heart, liver, kidney and fat tissue in patients treated with PBI-4050 over an average of 52 weeks
LAVAL, QC, April 12, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today positive clinical activity observed in Alström syndrome (AS) patients treated with PBI-4050 in the ongoing Phase 2 open label clinical trial being conducted
Apr 12, 2018 06:30 am ET
Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial
New clinical data presented at the International Liver CongressTM 2018
PBI-4050 decreased insulin resistance in the liver
Fat biopsies further demonstrate PBI-4050 clinical activity
Clinical activity measured in the heart, liver, kidney and fat tissue in patients treated with PBI-4050 over an average of 52 weeks
LAVAL, QC, April 12, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today positive clinical activity observed in Alström syndrome (AS) patients treated with PBI-4050 in the ongoing Phase 2 open label clinical trial being conducted
Apr 03, 2018 07:00 am ET
Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer
Bruce Wendel is an accomplished, senior pharma executive with 37 years of industry experience
LAVAL, QC, April 3, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announces today that Mr. Bruce Wendel is joining the Executive team as Chief Business Development Officer (CBDO), effective immediately. Mr. Wendel has been serving on the Board of Directors of Prometic Life Sciences Inc. since 2008. He has a long and impressive track record of business development and deal-making in the bio-pharma industry.
Apr 03, 2018 07:00 am ET
Prometic Announces Appointment of Bruce Wendel as Chief Business Development Officer
Bruce Wendel is an accomplished, senior pharma executive with 37 years of industry experience
LAVAL, QC, April 3, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announces today that Mr. Bruce Wendel is joining the Executive team as Chief Business Development Officer (CBDO), effective immediately. Mr. Wendel has been serving on the Board of Directors of Prometic Life Sciences Inc. since 2008. He has a long and impressive track record of business development and deal-making in the bio-pharma industry.
Mar 28, 2018 09:25 pm ET
Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients
Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment
Cardiac MRI indicates PBI-4050 reversed trend of fibrosis progression
Reduction in liver fibrosis in patients treated with PBI-4050 demonstrated by MRI and Fibroscan
Upcoming meetings with FDA and EMA to define PBI-4050's clinical-regulatory pathway in Alström syndrome
LAVAL, QC, March 28, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced new clinical data from its ongoing Phase 2 open label clinical trial being c
Mar 28, 2018 09:25 pm ET
Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Study in Alström Syndrome Patients
Clinical benefits in both heart and liver observed in patients treated with PBI-4050 over an average of 52 weeks of treatment
Cardiac MRI indicates PBI-4050 reversed trend of fibrosis progression
Reduction in liver fibrosis in patients treated with PBI-4050 demonstrated by MRI and Fibroscan
Upcoming meetings with FDA and EMA to define PBI-4050's clinical-regulatory pathway in Alström syndrome
LAVAL, QC, March 28, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced new clinical data from its ongoing Phase 2 open label clinical trial being c
Mar 28, 2018 08:59 pm ET
Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities
Lead drug candidates (PBI-4050 and RYPLAZIM™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data
52week average PBI-4050 treatment in Alström Syndrome patients generated positive clinical data indicating fibrosis reversal in multiple organs
FDA clearance to initiate PBI-4050 pivotal Phase 3 trial in patients with idiopathic pulmonary fibrosis
Update on RYPLAZIM™ (plasminogen) BLA review process – PDUFA action date
Update on deal with Shenzhen Royal Asset Management ("SRAM")
LAVAL, QC, March 28, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (
Mar 28, 2018 08:59 pm ET
Prometic Reports its Q4-2017 and YE-2017 Financial Results and Provides Update on Activities
Lead drug candidates (PBI-4050 and RYPLAZIM™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data
52week average PBI-4050 treatment in Alström Syndrome patients generated positive clinical data indicating fibrosis reversal in multiple organs
FDA clearance to initiate PBI-4050 pivotal Phase 3 trial in patients with idiopathic pulmonary fibrosis
Update on RYPLAZIM™ (plasminogen) BLA review process – PDUFA action date
Update on deal with Shenzhen Royal Asset Management ("SRAM")
LAVAL, QC, March 28, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (
Mar 26, 2018 07:00 am ET
Prometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / Webcast
LAVAL, QC, March 26, 2018 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the fourth quarter and financial year ended December 31, 2017 on Wednesday March 28, 2017 after market close.
Mar 26, 2018 07:00 am ET
Prometic to report its Fourth Quarter and Year-End 2017 Financial Results and hold Conference Call / Webcast
LAVAL, QC, March 26, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the fourth quarter and financial year ended December 31, 2017 on Wednesday March 28, 2017 after market close.
Mar 05, 2018 06:00 am ET
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
Rare Pediatric Disease Designation granted for the treatment of patients with necrotizing enterocolitis (NEC)
NEC accounts for approximately 19% of the US's annual neonatal medical expenditures as well as an estimated $5 Billion in annual hospitalization costs in the US
LAVAL, QC, March 5, 2018 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to its Inter-Alpha-Inhibitor-Proteins ("IaIp") for the treatment of Necrotizing Enterocolitis ("NEC"). In addit
Mar 05, 2018 06:00 am ET
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
Rare Pediatric Disease Designation granted for the treatment of patients with necrotizing enterocolitis (NEC)
NEC accounts for approximately 19% of the US's annual neonatal medical expenditures as well as an estimated $5 Billion in annual hospitalization costs in the US
LAVAL, QC, March 5, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to its Inter-Alpha-Inhibitor-Proteins ("IaIp") for the treatment of Necrotizing Enterocolitis ("NEC"). I
Feb 20, 2018 04:56 pm ET
Prometic Announces Realignment of its Clinical Program Priorities for 2018
IPF and Alström Syndrome; Top priorities for PBI-4050 clinical development
Unique anti-fibrotic mechanism of action supporting rationale for the development of first-in-class drug candidates
Plasminogen to target acute acquired deficiencies and wound healing
LAVAL, QC, Feb. 20, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today provided an update regarding its clinical development programs and confirmation of its priorities regarding its lead drug candidates.
Feb 20, 2018 04:56 pm ET
Prometic Announces Realignment of its Clinical Program Priorities for 2018
IPF and Alström Syndrome; Top priorities for PBI-4050 clinical development
Unique anti-fibrotic mechanism of action supporting rationale for the development of first-in-class drug candidates
Plasminogen to target acute acquired deficiencies and wound healing
LAVAL, QC, Feb. 20, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today provided an update regarding its clinical development programs and confirmation of its priorities regarding its lead drug candidates.
Feb 16, 2018 06:30 am ET
Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
New, previously undescribed pathway critical to fibrosis development with two receptors acting as "dual master switches"
Studies in knockout mice demonstrate that GPR40 is protective and GPR84 is deleterious in fibrotic diseases
PBI-4050's anti-fibrotic mechanism of action demonstrated to occur via simultaneous stimulation of GPR40 and inhibition of GPR84
LAVAL, QC, Feb. 16, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced the publication in the American Journal of Pathology, the official journal of the American Society of Investigatio
Feb 16, 2018 06:30 am ET
Prometic Announces Publication of PBI-4050's Novel Antifibrotic Mechanism of Action in American Journal of Pathology
New, previously undescribed pathway critical to fibrosis development with two receptors acting as "dual master switches"
Studies in knockout mice demonstrate that GPR40 is protective and GPR84 is deleterious in fibrotic diseases
PBI-4050's anti-fibrotic mechanism of action demonstrated to occur via simultaneous stimulation of GPR40 and inhibition of GPR84
LAVAL, QC, Feb. 16, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced the publication in the American Journal of Pathology, the official journal of the American Society of Investigatio
Feb 15, 2018 07:41 am ET
Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
Additional orphan drug designation added to growing portfolio of unique plasma-derived therapeutics
NEC is the most common acquired gastrointestinal disease in premature neonates and one of the leading causes of death in neonatal intensive care units
The economic cost of NEC is high, accounting for approximately 19% of neonatal expenditures and an estimated cost of $5 billion per year for hospitalizations in the USA
LAVAL, QC, Feb. 15, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that an orphan drug designation status has been gra
Feb 15, 2018 07:41 am ET
Prometic granted orphan drug designation by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
Additional orphan drug designation added to growing portfolio of unique plasma-derived therapeutics
NEC is the most common acquired gastrointestinal disease in premature neonates and one of the leading causes of death in neonatal intensive care units
The economic cost of NEC is high, accounting for approximately 19% of neonatal expenditures and an estimated cost of $5 billion per year for hospitalizations in the USA
LAVAL, QC, Feb. 15, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that an orphan drug designation status has been gra
Jan 29, 2018 05:30 am ET
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Clinical trial design confirmed during FDA Type C meeting held on January 3, 2018
Simplified patient entry criteria to include IPF patients whether on background standard of care (i.e. nintedanib) or not
Primary endpoint analysis to be stratified on background therapy (+/- nintedanib)
Planned Interim analysis at 26 weeks
Company to host IPF KOL luncheon presentation and live webcast for the investment community on January 31 at 12 noon EST
LAVAL, QC, Jan. 29, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announces today the outcome of a successfu
Jan 29, 2018 05:30 am ET
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Clinical trial design confirmed during FDA Type C meeting held on January 3, 2018
Simplified patient entry criteria to include IPF patients whether on background standard of care (i.e. nintedanib) or not
Primary endpoint analysis to be stratified on background therapy (+/- nintedanib)
Planned Interim analysis at 26 weeks
Company to host IPF KOL luncheon presentation and live webcast for the investment community on January 31 at 12 noon EST
LAVAL, QC, Jan. 29, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announces today the outcome of a successfu
Jan 25, 2018 01:01 pm ET
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
LAVAL, QC, Jan. 25, 2018 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced that it will host a Key Opinion Leader (KOL) meeting on the topic of novel treatments for idiopathic pulmonary fibrosis (IPF) on Wednesday, January 31 in New York City.
Jan 25, 2018 01:01 pm ET
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
LAVAL, QC, Jan. 25, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced that it will host a Key Opinion Leader (KOL) meeting on the topic of novel treatments for idiopathic pulmonary fibrosis (IPF) on Wednesday, January 31 in New York City.
Dec 18, 2017 09:46 am ET
Prometic's Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)
Ryplazim™ is Prometic's Second Orphan Drug Designation (ODD) Granted for IPF by the FDA
Two Late Stage Clinical Assets targeting IPF: Ryplazim™ under BLA review and PBI-4050 entering pivotal Phase 2/3 clinical trials.
LAVAL, QC, Dec. 18, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today that an orphan drug designation status has been granted to its Plasminogen (Ryplazim™) for the treatment of idiopathic pulmonary fibrosis ("IPF") by the US Food and Drug Administration (FDA).
Dec 18, 2017 09:46 am ET
Prometic's Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)
Ryplazim™ is Prometic's Second Orphan Drug Designation (ODD) Granted for IPF by the FDA
Two Late Stage Clinical Assets targeting IPF: Ryplazim™ under BLA review and PBI-4050 entering pivotal Phase 2/3 clinical trials.
LAVAL, QC, Dec. 18, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today that an orphan drug designation status has been granted to its Plasminogen (Ryplazim™) for the treatment of idiopathic pulmonary fibrosis ("IPF") by the US Food and Drug Administration (FDA).
Dec 11, 2017 06:00 am ET
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
LAVAL, QC, Dec. 11, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today that its orally-active drug candidate, PBI-4050, has been issued a Promising Innovative Medicine (PIM) designation by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) as add-on treatment to nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
Dec 11, 2017 06:00 am ET
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
LAVAL, QC, Dec. 11, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today that its orally-active drug candidate, PBI-4050, has been issued a Promising Innovative Medicine (PIM) designation by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) as add-on treatment to nintedanib in patients with idiopathic pulmonary fibrosis (IPF).
Dec 06, 2017 06:00 am ET
Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
Data demonstrates that the 100% resolution of lesions present at baseline is maintained at 48 weeks
LAVAL, QC, Dec. 6, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it will have two presentations at the 59th American Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.
Dec 06, 2017 06:00 am ET
Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
Data demonstrates that the 100% resolution of lesions present at baseline is maintained at 48 weeks
LAVAL, QC, Dec. 6, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it will have two presentations at the 59th American Society of Hematology (ASH) Annual Meeting being held Dec. 9-12, 2017 in Atlanta.
Dec 01, 2017 06:00 am ET
Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
LAVAL, QC, Dec. 1, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it has closed the USD $80 million (CAD $100 million) line of credit (the "Credit Facility") previously entered into with Structured Alpha LP ("SALP"), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc.
Dec 01, 2017 06:00 am ET
Prometic announces the closing of its USD $80 million (CAD $100 million) line of credit with Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
LAVAL, QC, Dec. 1, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it has closed the USD $80 million (CAD $100 million) line of credit (the "Credit Facility") previously entered into with Structured Alpha LP ("SALP"), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc.
Nov 22, 2017 06:00 am ET
Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Interim Clinical Data Shows Non Inferiority to Commercially-Approved Products for Primary Immunodeficiencies
Clinical Data Generated to Date to Constitute Clinical Package for Regulatory Filing purposes with Health Canada
LAVAL, QC, Nov. 22, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no signif
Nov 22, 2017 06:00 am ET
Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Interim Clinical Data Shows Non Inferiority to Commercially-Approved Products for Primary Immunodeficiencies
Clinical Data Generated to Date to Constitute Clinical Package for Regulatory Filing purposes with Health Canada
LAVAL, QC, Nov. 22, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no signif
Nov 13, 2017 08:21 pm ET
Prometic Reports 2017 Third Quarter Highlights and Financial Results
US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP
Plasminogen BLA accepted by FDA, PDUFA date fixed at April 14, 2018
Plasminogen granted rare pediatric disease designation by FDA and priority review status by Health Canada
PBI-4050 granted Fast Track designation for IPF and green light to initiate the pivotal phase 2/3 clinical trials
Conference call and live webcast at 11:00 am ET on Tuesday November 14
LAVAL, QC, Nov. 13, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today its unaudited financial resul
Nov 13, 2017 08:21 pm ET
Prometic Reports 2017 Third Quarter Highlights and Financial Results
US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP
Plasminogen BLA accepted by FDA, PDUFA date fixed at April 14, 2018
Plasminogen granted rare pediatric disease designation by FDA and priority review status by Health Canada
PBI-4050 granted Fast Track designation for IPF and green light to initiate the pivotal phase 2/3 clinical trials
Conference call and live webcast at 11:00 am ET on Tuesday November 14
LAVAL, QC, Nov. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced today its unaudited financial resul
Nov 09, 2017 08:06 am ET
Prometic to Report its Third Quarter 2017 Financial Results and to Hold Conference Call / Webcast
LAVAL, QC, Nov. 9, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that it will report its financial results for the third quarter ended September 30, 2017 on Monday November 13, 2017 after market close.
Nov 09, 2017 08:06 am ET
Prometic to Report its Third Quarter 2017 Financial Results and to Hold Conference Call / Webcast
LAVAL, QC, Nov. 9, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that it will report its financial results for the third quarter ended September 30, 2017 on Monday November 13, 2017 after market close.
Nov 02, 2017 01:49 pm ET
For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !
LAVAL, QC, Nov. 2, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("Prometic") is pleased to invite you to participate in a full week of online activities, dedicated to plasminogen deficiency awareness, from November 6 to 10, 2017.
Nov 01, 2017 08:00 am ET
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation
LAVAL, QC, Nov. 1, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence a clinical trial of its plasminogen therapy in patients suffering from chronic tympanic membrane perforation (chronic TMP).
Nov 01, 2017 08:00 am ET
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation
LAVAL, QC, Nov. 1, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence a clinical trial of its plasminogen therapy in patients suffering from chronic tympanic membrane perforation (chronic TMP).
Oct 26, 2017 08:00 am ET
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer Phase 2 clinical trial
LAVAL, QC, Oct. 26, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence a Phase 2 clinical trial of its plasminogen therapy in patients suffering from diabetic foot ulcer (DFU).
Oct 26, 2017 08:00 am ET
Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen diabetic foot ulcer Phase 2 clinical trial
LAVAL, QC, Oct. 26, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has received Swedish Medical Products Agency (MPA) Clinical Trial Application (CTA) approval to commence a Phase 2 clinical trial of its plasminogen therapy in patients suffering from diabetic foot ulcer (DFU).
Oct 25, 2017 08:00 am ET
Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF)
Fast track designation follows recent FDA approval of pivotal Phase 2/3 clinical trial in IPF
LAVAL, QC, Oct. 25, 2017 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF). The Fast Track designation follows the FDA's recent approval of Prometic's Investigational New Drug (IND) application and design of the pivotal Phase 2/3 clinical trial in patients with IPF.
Oct 25, 2017 08:00 am ET
Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF)
Fast track designation follows recent FDA approval of pivotal Phase 2/3 clinical trial in IPF
LAVAL, QC, Oct. 25, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBI-4050, a clinical candidate in development for idiopathic pulmonary fibrosis (IPF). The Fast Track designation follows the FDA's recent approval of Prometic's Investigational New Drug (IND) application and design of the pivotal Phase 2/3 clinical trial in patients with IPF.
Oct 23, 2017 06:30 am ET
Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
Transaction to bridge to expected plasminogen (RyplazimTM) revenues as well as other asset monetization events
Facility provides flexible drawdowns callable at Prometic's request
Laval, Qc, Oct. 23, 2017 /CNW Telbec/ -Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it has entered into a binding letter of intent to secure a USD $80 million (CAD $100 million) line of credit (the "Credit Facility") from Structured Alpha LP ("SALP"), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc. The first two tranches can be drawn wi
Oct 23, 2017 06:30 am ET
Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
Transaction to bridge to expected plasminogen (RyplazimTM) revenues as well as other asset monetization events
Facility provides flexible drawdowns callable at Prometic's request
Laval, Qc, Oct. 23, 2017 /PRNewswire/ -Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it has entered into a binding letter of intent to secure a USD $80 million (CAD $100 million) line of credit (the "Credit Facility") from Structured Alpha LP ("SALP"), an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc. The first two tranches can be drawn wi
Oct 20, 2017 02:20 pm ET
Prometic presents PBI-4050 and PBI-4547 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting
LAVAL, QC, Oct. 20, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announces in vivo data from compounds PBI-4050 and PBI-4547 for the prevention and treatment of liver diseases, and associated metabolic syndrome are being presented in three poster sessions at AASLD (The Liver Meeting®) in Washington, D.C. from Oct. 20-24, 2017.
Oct 20, 2017 02:20 pm ET
Prometic presents PBI-4050 and PBI-4547 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting
LAVAL, QC, Oct. 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announces in vivo data from compounds PBI-4050 and PBI-4547 for the prevention and treatment of liver diseases, and associated metabolic syndrome are being presented in three poster sessions at AASLD (The Liver Meeting®) in Washington, D.C. from Oct. 20-24, 2017.
Oct 19, 2017 07:30 am ET
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)
Prometic plans to file its NDS with Health Canada in the fourth quarter of 2017
LAVAL, QC, Oct. 19, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency.
Oct 19, 2017 07:30 am ET
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)
Prometic plans to file its NDS with Health Canada in the fourth quarter of 2017
LAVAL, QC, Oct. 19, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Health Canada has granted priority review status for the New Drug Submission (NDS) the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency.
Oct 13, 2017 07:30 am ET
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
Prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018
Ryplazim™ previously granted Fast Track, Rare Pediatric Disease and Orphan Drug Designations by U.S. FDA
LAVAL, QC, Oct. 13, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action date for April 14, 2018, Ryplazim™ had p
Oct 13, 2017 07:30 am ET
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
Prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018
Ryplazim™ previously granted Fast Track, Rare Pediatric Disease and Orphan Drug Designations by U.S. FDA
LAVAL, QC, Oct. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its plasminogen replacement therapy (RyplazimTM) having granted a priority review status and set a Prescription Drug User Fee Act (PDUFA) action date for April 14, 2018, Ryplazim™ had p
Sep 25, 2017 07:30 am ET
Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis
Prometic moving immediately to formalize enrollment of specialist clinical sites across the United States
U.S. IND to be followed by clinical trial applications in Canada, Europe, Australia and Japan throughout Q4 2017
Prometic plans to supplement the IND with a protocol for a study of PBI-4050 monotherapy in IPF patients in October 2017
LAVAL, QC, Sept. 25, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that its oral anti-fibrotic lead drug candidate, PBI-4050, has received U.S. Food and Drug Administration Investigational New Drug (I
Sep 25, 2017 07:30 am ET
Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis
Prometic moving immediately to formalize enrollment of specialist clinical sites across the United States
U.S. IND to be followed by clinical trial applications in Canada, Europe, Australia and Japan throughout Q4 2017
Prometic plans to supplement the IND with a protocol for a study of PBI-4050 monotherapy in IPF patients in October 2017
LAVAL, QC, Sept. 25, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that its oral anti-fibrotic lead drug candidate, PBI-4050, has received U.S. Food and Drug Administration Investigational New Drug (I
Sep 19, 2017 07:30 am ET
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
Sustained safety observed over 48 weeks of treatment
Beneficial clinical effects in liver sustained over 48 weeks of treatment
Positive results support requests for meetings with both FDA and EMA to define the clinical-regulatory pathway for approval of PBI-4050 for the treatment of Alström syndrome
LAVAL, QC, Sept. 19, 2017 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that longer-term data from its on-going phase 2 open label clinical trial in subjects suffering from Alström Syndrome in the United Kingdom confirm that the beneficial clinical e
Sep 19, 2017 07:30 am ET
Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients
Sustained safety observed over 48 weeks of treatment
Beneficial clinical effects in liver sustained over 48 weeks of treatment
Positive results support requests for meetings with both FDA and EMA to define the clinical-regulatory pathway for approval of PBI-4050 for the treatment of Alström syndrome
LAVAL, QC, Sept. 19, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that longer-term data from its on-going phase 2 open label clinical trial in subjects suffering from Alström Syndrome in the United Kingdom confirm that the beneficial cli
Sep 11, 2017 07:30 am ET
/R E P E A T -- Prometic to Present at Two U.S. Investor Conferences in September/
LAVAL, QC, Sept. 8, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Pierre Laurin, President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley Global Healthcare Conference, and the Cantor Fitzgerald Global Healthcare Conference in September.
Sep 11, 2017 07:30 am ET
/R E P E A T -- Prometic to Present at Two U.S. Investor Conferences in September/
LAVAL, QC, Sept. 8, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Pierre Laurin, President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley Global Healthcare Conference, and the Cantor Fitzgerald Global Healthcare Conference in September.
Sep 08, 2017 06:34 pm ET
Prometic to Present at Two U.S. Investor Conferences in September
LAVAL, QC, Sept. 8, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Pierre Laurin, President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley Global Healthcare Conference, and the Cantor Fitzgerald Global Healthcare Conference in September.
Sep 08, 2017 06:34 pm ET
Prometic to Present at Two U.S. Investor Conferences in September
LAVAL, QC, Sept. 8, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that Pierre Laurin, President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley Global Healthcare Conference, and the Cantor Fitzgerald Global Healthcare Conference in September.
Sep 08, 2017 06:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
The Annual Review of the S&P/TSX SmallCap Index
Aug 29, 2017 07:30 am ET
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy
Triple designation of orphan drug, fast track status, combined with rare pediatric designation, underscores significant unmet need for therapy
LAVAL, QC, Aug. 29, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to Prometic's Ryplazimä, a plasminogen replacement therapy for the treatment of patients with congenital plasminogen deficiency. In addition to the Rare Pediatric Disease Designation, Ryplazimä has already been granted Orphan Drug a
Aug 29, 2017 07:30 am ET
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy
Triple designation of orphan drug, fast track status, combined with rare pediatric designation, underscores significant unmet need for therapy
LAVAL, QC, Aug. 29, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to Prometic's Ryplazimä, a plasminogen replacement therapy for the treatment of patients with congenital plasminogen deficiency. In addition to the Rare Pediatric Disease Designation, Ryplazimä has already been granted Orphan Drug a
Aug 14, 2017 08:18 pm ET
Prometic Reports 2017 Second Quarter Highlights and Financial Results
$101 million of new 2017 cash inflows closed from debt, equity & corporate transactions
On-going review of plasminogen BLA with the U.S. FDA
48-week clinical data from plasminogen phase 2/3 trial confirms no recurrence of lesions, no safety or tolerability issues observed.
Concurrence from the FDA on the design of PBI-4050's planned phase 2/3 pivotal clinical trial for Idiopathic Pulmonary Fibrosis
24-week clinical data confirm efficacy and safety of PBI-4050 maintained in metabolic syndrome & diabetic patients
LAVAL, QC, Aug. 14, 2017 /CNW Telbec/ - Prometic Life Sciences Inc
Aug 14, 2017 07:30 am ET
Prometic and Shenzhen Royal Asset Management Close Transaction for Joint Venture and Licensing Rights to PBI-4050, PBI-4547 and PBI-4425 in China
Deal provides Prometic with an initial $33 million, of which $23 million receivable in H2 2017
SRAM acquired a Chinese pharmaceutical company to serve as development and commercial platform
LAVAL, QC, Aug. 14, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has executed definitive agreements in relation to the previously announced joint venture with affiliates of Shenzhen Royal Asset Management Co., Ltd. (SRAM).
Aug 14, 2017 07:30 am ET
Prometic and Shenzhen Royal Asset Management Close Transaction for Joint Venture and Licensing Rights to PBI-4050, PBI-4547 and PBI-4425 in China
Deal provides Prometic with an initial $33 million, of which $23 million receivable in H2 2017
SRAM acquired a Chinese pharmaceutical company to serve as development and commercial platform
LAVAL, QC, Aug. 14, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that it has executed definitive agreements in relation to the previously announced joint venture with affiliates of Shenzhen Royal Asset Management Co., Ltd. (SRAM).
Aug 08, 2017 08:30 am ET
Prometic to Report its Second Quarter 2017 Financial Results and to Hold Conference Call / Webcast
LAVAL, QC, Aug. 8, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") today announced that it will report its financial results for the second quarter ended June 30, 2017 on Monday August 14, 2017 after market close.
Jul 11, 2017 07:30 am ET
Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
Ryplazym™ (Plasminogen IV) long-term treatment shown to prevent recurrence of lesions at 48 weeks
Ryplazym™ (Plasminogen IV) maintains the same safety, tolerability profile without any serious adverse events at 48 weeks
FDA inspection of RyplazymTM manufacturing facility, as part of ongoing BLA evaluation, currently scheduled for summer 2017
48-week data to form basis of regulatory filing with Health Canada in 4Q 2017
LAVAL, QC, July 11, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced new long-term clinical data
Jul 11, 2017 07:30 am ET
Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
Ryplazym™ (Plasminogen IV) long-term treatment shown to prevent recurrence of lesions at 48 weeks
Ryplazym™ (Plasminogen IV) maintains the same safety, tolerability profile without any serious adverse events at 48 weeks
FDA inspection of RyplazymTM manufacturing facility, as part of ongoing BLA evaluation, currently scheduled for summer 2017
48-week data to form basis of regulatory filing with Health Canada in 4Q 2017
LAVAL, QC, July 11, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced new long-term clinical data
Jul 06, 2017 10:19 am ET
Prometic announces closing of equity offerings for aggregate gross proceeds of $61.7 million
Substantial participation from U.S. institutional investors
Structured Alpha LP ("SALP"), an investment vehicle of Peter J. Thomson, continues its support through an $8.6 million private placement investment in common shares
LAVAL, QC, July 6, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the previously announced $53.1 million bought deal equity offering of common shares in the capital of the Corporation (the "Offering") through a syndicate of underwriters led by Cantor Fitzgerald Canada Corpo
Jul 06, 2017 10:19 am ET
Prometic announces closing of equity offerings for aggregate gross proceeds of $61.7 million
Substantial participation from U.S. institutional investors
Structured Alpha LP ("SALP"), an investment vehicle of Peter J. Thomson, continues its support through an $8.6 million private placement investment in common shares
LAVAL, QC, July 6, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the previously announced $53.1 million bought deal equity offering of common shares in the capital of the Corporation (the "Offering") through a syndicate of underwriters led by Cantor Fitzgerald Canada Corpo
Jun 15, 2017 05:55 pm ET
Prometic Announces $53 Million Bought Deal Offering
**NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES**
Jun 12, 2017 07:30 am ET
Jun 12, 2017 07:30 am ET
May 23, 2017 07:30 am ET
Prometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 International Conference
PBI-4050 monotherapy and combination with nintedanib demonstrated promising results in the treatment of Idiopathic Pulmonary Fibrosis (IPF)
Data on PBI-4050 regulation of proteins involved in human lung fibrosis
Plasminogen administration shown to reduce acute lung injury (ALI) in an acute pancreatitis model
PBI-4425 shown to reduce pulmonary emphysema in a scleroderma mouse model
LAVAL, QC, May 23, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") presented new data at the 2017 American Thoracic Society (ATS) International Confere
May 23, 2017 07:30 am ET
Prometic Presents New Data on PBI-4050 and Plasminogen at the American Thoracic Society's 2017 International Conference
PBI-4050 monotherapy and combination with nintedanib demonstrated promising results in the treatment of Idiopathic Pulmonary Fibrosis (IPF)
Data on PBI-4050 regulation of proteins involved in human lung fibrosis
Plasminogen administration shown to reduce acute lung injury (ALI) in an acute pancreatitis model
PBI-4425 shown to reduce pulmonary emphysema in a scleroderma mouse model
LAVAL, QC, May 23, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") presented new data at the 2017 American Thoracic Society (ATS) International Confere
May 15, 2017 08:33 pm ET
Prometic Reports 2017 First Quarter Highlights and Financial Results
$69.3 million in new 2017 cash inflows from transactions negotiated in Q1
$21.1 million from warrants exercise received in Q1
$25.0 million from the Structured Alpha financing received in Q2
$23.2 million cash to follow in 2017 from the SRAM China transaction
PBI-4050s' clinical efficacy confirmed in completed IPF open label phase 2 clinical trial - PBI-4050 advancing into placebo controlled phase 2/3 clinical trials for IPF and CKD
Rolling submission of the plasminogen BLA with the U.S. FDA completed
LAVAL, QC, May 15, 2017 /CNW/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)
May 10, 2017 07:23 pm ET
Prometic reports its 2017 annual and special meeting of shareholders highlights
PBI-4050 clinical efficacy demonstrated and confirmed in metabolic syndrome and type 2 diabetes, IPF and Alström syndrome patients
Plasminogen's clinical efficacy demonstrated and confirmed in plasminogen deficient patients
Rolling submission of Plasminogen BLA completed
Commercial infrastructure and flexible business model to facilitate plasminogen commercial launch
PBI-4050 advancing into placebo controlled phase 2/3 clinical trials for IPF and CKD
Significant cash inflows already secured in 2017
LAVAL, QC, May 10, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSC
May 08, 2017 08:00 am ET
Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference
Plasminogen administration shown to reduce acute lung injury ("ALI") in an acute pancreatitis model
ALI and its more severe form, acute respiratory distress syndrome ("ARDS") represent large unmet medical needs
ALI and ARDS affect approximately 190,000 patients / year in the US with a mortality rate of close to 40%
LAVAL, QC, May 8, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will be presenting new data at the 2017 American Thoracic Society ("ATS") International Conference in Washington, D.C. showing t
May 08, 2017 08:00 am ET
Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference
Plasminogen administration shown to reduce acute lung injury ("ALI") in an acute pancreatitis model
ALI and its more severe form, acute respiratory distress syndrome ("ARDS") represent large unmet medical needs
ALI and ARDS affect approximately 190,000 patients / year in the US with a mortality rate of close to 40%
LAVAL, QC, May 8, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will be presenting new data at the 2017 American Thoracic Society ("ATS") International Conference in Washington, D.C. showing t
Apr 28, 2017 08:00 am ET
Prometic Announces the Closing of the $25 Million Follow-On Financing From Structured Alpha LP, an Affiliate of Thomvest Asset Management Inc.
LAVAL, QC, April 28, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management Inc., consisting of a $25 million loan (the "Loan").
Apr 20, 2017 08:00 am ET
Prometic's PBI-4050 Shown to Reduce Liver Damage and Fibrosis in High-Fat Diet Induced Obesity and Metabolic Syndrome Mouse Model
Strong correlation of results with phase 2 clinical data in metabolic syndrome with type 2 diabetes patients
New data presented at ILC 2017 EASL conference
LAVAL, QC, April 20, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today presented new results at the International Liver Congress ("ILC") 2017 of the European Association for the Study of the Liver ("EASL") in Amsterdam on the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis (NASH) in a mouse model of obesity and metabolic syndrome.
Apr 20, 2017 08:00 am ET
Prometic's PBI-4050 Shown to Reduce Liver Damage and Fibrosis in High-Fat Diet Induced Obesity and Metabolic Syndrome Mouse Model
Strong correlation of results with phase 2 clinical data in metabolic syndrome with type 2 diabetes patients
New data presented at ILC 2017 EASL conference
LAVAL, QC, April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today presented new results at the International Liver Congress ("ILC") 2017 of the European Association for the Study of the Liver ("EASL") in Amsterdam on the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis (NASH) in a mouse model of obesity and metabolic syndrome.
Apr 18, 2017 08:00 am ET
FDA confirms Prometic's PBI-4050 IPF clinical trial design
FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with nintedanib
Prometic to also conduct placebo controlled phase 2/3 PBI-4050 Monotherapy clinical trial
LAVAL, QC, April 18, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has received concurrence from the US Food and Drug Administration ("FDA") on the design of the first of its PBI-4050's planned phase 2/3 clinical trials for IPF based on the efficacy data generated in the recently completed 40 patient Phase
Apr 18, 2017 08:00 am ET
FDA confirms Prometic's PBI-4050 IPF clinical trial design
FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with nintedanib
Prometic to also conduct placebo controlled phase 2/3 PBI-4050 Monotherapy clinical trial
LAVAL, QC, April 18, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has received concurrence from the US Food and Drug Administration ("FDA") on the design of the first of its PBI-4050's planned phase 2/3 clinical trials for IPF based on the efficacy data generated in the recently completed 40 patient Phase
Apr 07, 2017 08:00 am ET
Prometic Receives $9.5 Million Purchase Order From Multinational Client
LAVAL, QC, April 7, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has received a $9.5 million purchase order for the supply of affinity resin to an existing client, a global leader in the biopharmaceutical industry.
Apr 07, 2017 08:00 am ET
Prometic Receives $9.5 Million Purchase Order From Multinational Client
LAVAL, QC, April 7, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has received a $9.5 million purchase order for the supply of affinity resin to an existing client, a global leader in the biopharmaceutical industry.
Apr 05, 2017 07:00 am ET
Prometic completes the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA
LAVAL, QC, April 5, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has completed the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA for the treatment of patients with plasminogen congenital deficiency.
Apr 05, 2017 07:00 am ET
Prometic completes the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA
LAVAL, QC, April 5, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has completed the filing of its plasminogen Biologics License Application ("BLA") with the U.S. FDA for the treatment of patients with plasminogen congenital deficiency.
Mar 30, 2017 11:48 pm ET
Prometic Reports its 2016 Fourth Quarter and Year End Highlights and Financial Results
Clinical efficacy of PBI-4050 confirmed in multiple phase 2 trials: Idiopathic Pulmonary Fibrosis, metabolic syndrome and Alström syndrome
Clinical efficacy of plasminogen confirmed in completed pivotal phase 2/3 clinical trial
Rolling submission of plasminogen BLA initiated
Significant manufacturing and commercial infrastructure secured to enable plasma derived therapeutics commercial launches accounts for material increase in net loss
Plasma protein manufacturing investment represents 37% of R&D costs in 2016
Potential further integration of manufacturing capability and longer te
Mar 30, 2017 08:00 am ET
Prometic and Shenzhen Royal Asset management (SRAM) to establish a joint venture to develop, manufacture and commercialize PBI-4050, PBI-4547 AND PBI-4425 in China
Prometic to own 75% of the Joint Venture following SRAM's $33 million investment
Proceeds earmarked to support clinical development in North America & Europe
Prometic to benefit from extensive networking and track record of SRAM in Chinese Healthcare Space
Joint Venture's Initial Focus on treatment of Diabetic Kidney Disease, Lung and Liver Fibrosis
LAVAL, QC, March 30, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has entered into a binding Memorandum of Terms with Shenzhen Royal Asset Management
Mar 24, 2017 07:30 am ET
Prometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
Total investment in Prometic from Peter J. Thomson's Toronto-based investment vehicle amounting to $85 million
$25 Million debt financing to bear interest of 8.5% per annum and repayable in July, 2022
No material additional security to be granted by Prometic over and beyond the existing debt package
10,600,407 warrants to be granted at an exercise price of $3.70, a premium of 70% to the most recent Prometic share price close
Aggregate proceeds from exercise of warrants to offset the total amount repayable under the debt instrument
LAVAL, QC, March 24, 2017 /CNW Telbec/ - Prometic Life
Mar 23, 2017 08:00 am ET
Prometic to Report its Fourth Quarter and Year-end 2016 Financial Results and Hold Conference Call / Webcast
LAVAL, QC, March 23, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") today announced that it will report its financial results for the fourth quarter and financial year ended December 31, 2016 on Thursday March 30, 2017 after market close.
Mar 03, 2017 06:30 am ET
US FDA Grants Orphan Drug Designation to Prometic's PBI-4050 Drug for the Treatment of Alström Syndrome
LAVAL, QC, March 3, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announces that an orphan drug designation status has been granted, by the United States Food and Drug Administration, for its orally active, anti-fibrotic, lead drug candidate, PBI-4050, for the treatment of Alstrӧm Syndrome ("AS").
Feb 22, 2017 06:30 am ET
ProMetic's PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis Phase 2 clinical trial
Early evidence of efficacy of PBI-4050 as a monotherapy and in combination with one of the commercially available drugs confirmed
PBI-4050 continues to be very well tolerated, whether used alone or in combination with nintedanib or pirfenidone
LAVAL, QC, Feb. 22, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today positive results from its completed open label Phase 2 clinical trial in subjects suffering from idiopathic pulmonary fibrosis ("IPF"). In addition to demonstrating that PBI-4050 is safe and very well tole
Feb 16, 2017 10:09 am ET
IIROC Trade Resumption - PLI
TORONTO, Feb. 16, 2017 /CNW/ - Trading resumes in:
Feb 16, 2017 10:01 am ET
IIROC Trading Halt - PLI
TORONTO, Feb. 16, 2017 /CNW/ - The following issues have been halted by IIROC:
Feb 06, 2017 06:30 am ET
California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants
LAVAL, QC, Feb. 6, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that California Capital Equity, LLC, has exercised 44,791,488 share purchase warrants at a price of $0.47 per share for total proceeds of $21,051,999.36 to the Corporation.
Feb 06, 2017 06:30 am ET
California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants
LAVAL, QC, Feb. 6, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that California Capital Equity, LLC, has exercised 44,791,488 share purchase warrants at a price of $0.47 per share for total proceeds of $21,051,999.36 to the Corporation.
Jan 24, 2017 06:30 am ET
/R E P E A T -- ProMetic's PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome/
LAVAL, QC, Jan. 24, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been issued a Promising Innovative Medicine ("PIM") designation by the UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for the treatment of Alström Syndrome ("AS").
Jan 24, 2017 02:59 am ET
ProMetic's PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome
LAVAL, QC, Jan. 24, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been issued a Promising Innovative Medicine ("PIM") designation by the UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for the treatment of Alström Syndrome ("AS").
Jan 24, 2017 02:59 am ET
ProMetic's PBI-4050 receives promising innovative medicine designation from the UK MHRA for the treatment of Alström Syndrome
LAVAL, QC, Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been issued a Promising Innovative Medicine ("PIM") designation by the UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for the treatment of Alström Syndrome ("AS").
Jan 18, 2017 07:15 am ET
European Commission grants orphan drug designation to ProMetic's PBI-4050 drug for the treatment of Alström Syndrome
LAVAL, QC, Jan. 18, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been granted an orphan drug designation status for the treatment of Alström Syndrome ("AS") by the European Commission.
Jan 18, 2017 07:15 am ET
European Commission grants orphan drug designation to ProMetic's PBI-4050 drug for the treatment of Alström Syndrome
LAVAL, QC, Jan. 18, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that its orally active lead drug candidate, PBI-4050, has been granted an orphan drug designation status for the treatment of Alström Syndrome ("AS") by the European Commission.
Jan 05, 2017 06:30 am ET
ProMetic reacquires plasminogen rights from Hematech
Regains 100% ownership of profits from future sales of plasminogen for congenital deficiency
Hematech continues to hold Taiwanese rights to PPPS™ as CMO supplier to ProMetic
LAVAL, QC, Jan. 5, 2017 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today that it has amended its licensing agreement originally entered into with Hematech BioTherapeutics Inc., ("Hematech") in May 2012 (the "License Agreement"). ProMetic has reacquired the rights initially granted to Hematech in the License Agreement, to a 50% share of the worldw
Dec 19, 2016 06:30 am ET
ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA
LAVAL, QC, Dec. 19, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has initiated the rolling submission of its Biologics License Application ("BLA") for plasminogen with the U.S. FDA for treatment of patients with plasminogen congenital deficiency. ProMetic's plasminogen was granted Orphan Drug and Fast Track Designations by the FDA. The Fast Track designation allows rolling submissions of portions of the regulatory application to be submitted and reviewed by the FDA on an ongoing basis.
Dec 19, 2016 06:30 am ET
ProMetic initiates rolling submission of its Biologics License Application ("BLA") for plasminogen with U.S. FDA
LAVAL, QC, Dec. 19, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has initiated the rolling submission of its Biologics License Application ("BLA") for plasminogen with the U.S. FDA for treatment of patients with plasminogen congenital deficiency. ProMetic's plasminogen was granted Orphan Drug and Fast Track Designations by the FDA. The Fast Track designation allows rolling submissions of portions of the regulatory application to be submitted and reviewed by the FDA on an ongoing basis.
Dec 16, 2016 03:11 pm ET
ProMetic comments on unusual trading activity
LAVAL, QC, Dec. 16, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") responded today at the request of the Investment Industry Regulatory Organization of Canada ("IIROC") on behalf of the Toronto Stock Exchange, that it is not aware of any undisclosed material change to the Corporation's business or operations that would cause today's movement in the Corporation's share price and has no material change to report at this time.
Dec 09, 2016 09:00 am ET
ProMetic responds to false market data report regarding insider selling
LAVAL, QC, Dec. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation") responded today to a false market data report listing amongst others, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic, as a net seller of 8.85 million shares of ProMetic. This report is false and inaccurate. All insider activities, including those of Mr. Laurin, have been properly disclosed and filed on SEDI. Furthermore, the Corporation is unaware of any corporate developments to account for the recent decline in share price and trading activit
Nov 18, 2016 12:36 pm ET
ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
LAVAL, QC, Nov. 18, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today announced that it is presenting new data at the American Society of Nephrology's ("ASN") Annual Meeting currently underway in Chicago, with respect to ProMetic's anti-fibrotic and orally active lead drug candidate, PBI-4050.
Nov 18, 2016 12:36 pm ET
ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
LAVAL, QC, Nov. 18, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today announced that it is presenting new data at the American Society of Nephrology's ("ASN") Annual Meeting currently underway in Chicago, with respect to ProMetic's anti-fibrotic and orally active lead drug candidate, PBI-4050.
Nov 17, 2016 06:30 am ET
Nov 17, 2016 06:30 am ET
ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial
Early evidence of efficacy of PBI-4050 alone and also in combination with one of the commercially available IPF drugs
PBI-4050 shown to be very well tolerated whether used alone or in combination with nintedanib or pirfenidone
LAVAL, QC, Nov. 17, 2016 /PRNewswire/ -- ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today positive interim results from its Open Label Phase 2 clinical trial in patients suffering from idiopathic pulmonary fibrosis ("IPF"). In addition to demonstrating that PBI-4050 is safe and well tolerated in patients sufferi
Nov 16, 2016 06:30 am ET
ProMetic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes
LAVAL, QC, Nov. 16, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today reported that it has received clearance by Health Canada to commence a placebo-controlled phase 2 clinical trial with its PBI-4050, the company's orally active, lead small molecule anti-fibrosis drug candidate, in patients with metabolic syndrome and type 2 diabetes.
Nov 14, 2016 08:07 pm ET
ProMetic reports third quarter 2016 highlights and financial results
Acquisition of Telesta Therapeutics adds $37.4 million in cash and short-term investments to $39.0 million balance reported at end of Q3
Investment in commercial & manufacturing infrastructure ahead of plasminogen commercial launch included in R&D expense
Plasminogen pivotal clinical trial results performed at 100% response rate meeting primary and secondary end points in plasminogen deficient patients
Primary and secondary endpoints met in clinical trials in metabolic syndrome patients
2016 YTD revenues of $12.3 million vs. $10.5 million for same 2015 period
LAVAL, QC, Nov.
Nov 14, 2016 06:30 am ET
ProMetic's PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure with reduced ejection fraction ("HFrEF")
Over 5 million Americans suffer from heart failure, the majority having HFrEF
The presence of pulmonary hypertension ("PH") with HFrEF significantly increases mortality rate
No approved treatment exists for PH with left heart disease ("Group 2 PH")
New data from research conducted at the Montreal Heart Institute presented at the American Heart Association Annual Meeting in New Orleans
LAVAL, QC, Nov. 14, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today presented new results at the American Heart Association's (AHA) Annual
Nov 14, 2016 06:30 am ET
ProMetic's PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure with reduced ejection fraction ("HFrEF")
Over 5 million Americans suffer from heart failure, the majority having HFrEF
The presence of pulmonary hypertension ("PH") with HFrEF significantly increases mortality rate
No approved treatment exists for PH with left heart disease ("Group 2 PH")
New data from research conducted at the Montreal Heart Institute presented at the American Heart Association Annual Meeting in New Orleans
LAVAL, QC, Nov. 14, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today presented new results at the American Heart Association's (AHA) Annual
Nov 09, 2016 03:12 pm ET
Prometic to report its third quarter 2016 financial results and hold conference call / webcast
LAVAL, QC, Nov. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it will report its financial results for the third quarter ended September 30, 2016 on Monday November 14, 2016 after market close.
Oct 31, 2016 09:59 am ET
ProMetic announces closing of Telesta Therapeutics Inc. acquisition
Provides approximately $34 million in cash to be deployed towards drug development and clinical programs;
Provides up to $50 million in potential tax attributes;
Provides the opportunity for further integration of manufacturing capability and capacity expansion in a 150,000 sq. ft. facility in Belleville, Ontario; and
Provides significant foothold in Ontario and consolidates presence as a major plasma-derived therapeutics player in Canada.
LAVAL, QC, Oct 31, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that
Oct 26, 2016 07:30 am ET
ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial
100% success rate on meeting clinical trial's primary end points required for Accelerated Approval Regulatory Pathway
100% clinical response rate with healing of lesions within weeks of treatment
Successful pre-BLA meeting held with FDA
ProMetic to commence filing plasminogen BLA modules with the FDA as planned in coming weeks
LAVAL, QC, Oct. 26, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that its pivotal Phase 2/3 clinical trial in patients with plasminogen deficiency has met its primary and secondary end
Oct 20, 2016 07:30 am ET
ProMetic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes Phase 2 clinical trial
Clinically and statistically significant reduction of glycated hemoglobin ("HbA1c") originally observed at 12 weeks is maintained at 24 weeks of treatment
Clinically and statistically significant reduction of waist circumference (a fundamental metabolic syndrome criterion)
Statistical improvement of new biomarkers related to kidney injury
Placebo-controlled clinical trial to commence this quarter
LAVAL, QC, Oct. 20, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that its Phase 2 clinical trial in patients with
Oct 12, 2016 07:00 am ET
ProMetic's PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alström Syndrome
Significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment
Liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment
Alström syndrome clinical program to be expanded to include further sites throughout Europe and North America
LAVAL, QC, Oct. 12, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that the Drug Safety Monitoring Board ("DSMB") recommended that patient enrolment should continue in the
Oct 12, 2016 07:00 am ET
ProMetic's PBI-4050 Significantly Reduces Liver Fibrosis in Patients with Alström Syndrome
Significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment
Liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment
Alström syndrome clinical program to be expanded to include further sites throughout Europe and North America
LAVAL, QC, Oct. 12, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that the Drug Safety Monitoring Board ("DSMB") recommended that patient enrolment should continue in the
Sep 06, 2016 06:30 am ET
ProMetic announces the addition of tympanic membrane perforations (TMPs) to its plasminogen's targeted indications
Over 100,000 surgeries performed annually in the USA alone for persistent tympanic perforations
New Plasminogen formulation optimized for wound healing indications
Global patent protection for this new indication secured through Omnio partnership
LAVAL, QC, Sept. 6, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today announced that it will be pursuing tympanic membrane perforations ("TMP"), as one of its new plasma-derived plasminogen targeted clinical indications. ProMetic expects to file its clinical trial application ("CTA
Aug 24, 2016 07:00 am ET
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
LAVAL, QC, Aug. 24, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has entered into a binding agreement (the "Agreement") for the acquisition of Telesta Therapeutics, Inc, ("Telesta") by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition").
Aug 24, 2016 07:00 am ET
ProMetic announces agreement to acquire Telesta Therapeutics Inc. in all share transaction
LAVAL, QC, Aug. 24, 2016 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has entered into a binding agreement (the "Agreement") for the acquisition of Telesta Therapeutics, Inc, ("Telesta") by way of a plan of arrangement under the Canada Business Corporations Act (the "Acquisition").
Aug 11, 2016 05:56 pm ET
ProMetic reports second quarter 2016 highlights and financial results
PBI-4050 clinical efficacy further evidenced in metabolic syndrome and type 2 diabetes patients
Plasminogen FDA fast track designation secured, clinical efficacy further evidenced in plasminogen deficient patients
Strengthened balance sheet with closing of $60.1 million bought deal equity financing
H1 2016 revenues of $8.5 million vs. $4.8 million for H1 2015
LAVAL, QC, Aug. 11, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") today reported revenues of $3.3 million for the second quarter ended June 30, 2016 compared to $2.9 m
Aug 11, 2016 07:15 am ET
Prometic completes patients' enrolment in pivotal plasminogen phase 2/3 clinical trial
Patients enrolment for the accelerated regulatory approval pathway completed
Filing of Biologics License Application ("BLA") to start in Q4 2016
LAVAL, QC, Aug. 11, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the Food and Drug Administration ("FDA").
Aug 09, 2016 07:30 am ET
ProMetic Completes Adult Patients' Enrolment in Pivotal IVIG Phase 3 Clinical Trial
Milestone achieved five months ahead of schedule
ProMetic well positioned to become first Canadian provider of locally manufactured IVIG to serve rapidly growing Canadian market
LAVAL, QC, Aug. 9, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it has completed the enrolment of the adult patient population (50 adult patients) in its pivotal IVIG phase III clinical trial for the treatment of primary immunodeficiency diseases ("PIDD").
Aug 02, 2016 11:49 am ET
Prometic to report its second quarter 2016 financial results and hold conference call / webcast
LAVAL, QC, Aug. 2, 2016 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today that it will report its financial results for the second quarter ended June 30, 2016 on Thursday August 11, 2016 after market close.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.